Newly FDA Approved AMVUTTRA™ for Treatment of hATTR Amyloidosis with Polyneuropathy

Robert L. Gottlieb, MD, PhD, FACC is a cardiologist in Dallas, Texas. Dr. Gottlieb will discuss what hereditary transthyretin-mediated (hATTR) amyloidosis is, the impact this rare and debilitating disease may have on those living with it, and a new therapeutic option recently approved by the U.S. FDA to treat the polyneuropathy manifestations associated with it.

Robert L. Gottlieb, MD, PhD, FACC is a cardiologist in Dallas, Texas. Dr. Gottlieb is board certified by the American Board of Internal Medicine in Cardiovascular Disease and Advanced Heart Failure and Transplant Cardiology. After completing his Master of Genetics from Yale University, he earned his PhD in Chemistry and RNA Biochemistry from the University of Colorado at Boulder. He received his medical degree from the University of Colorado School of Medicine and completed his post-graduate training, including a fellowship in Advanced Heart Failure and Transplant Cardiology, at the University of Iowa Hospitals and Clinics.